BLSM (BlossomHill Therapeutics) Institutional Ownership: 0.00% (As of Aug. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BLSM BlossomHill Therapeutics Inc BLSM
8 GF Score
Price $16.02
View Full Analysis

What is BlossomHill Therapeutics Institutional Ownership?

BlossomHill Therapeutics BLSM +0.12% 8 Institutional Ownership is 0.00% as of Aug. 10, 2026. GuruFocus rates BLSM with a GF Score™ of 8/100.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, BlossomHill Therapeutics's institutional ownership is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, BlossomHill Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, BlossomHill Therapeutics's Float Percentage Of Total Shares Outstanding is N/A.

BlossomHill Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for BlossomHill Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BlossomHill Therapeutics Institutional Ownership Chart

BlossomHill Therapeutics Annual Data
Trend Dec24 Dec25
Institutional Ownership
0.00 0.00

BlossomHill Therapeutics Semi-Annual Data
Dec24 Dec25
Institutional Ownership 0.00 0.00
BLSM
8GF Score
BlossomHill Therapeutics Inc BLSM
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BlossomHill Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.00% mean?
BlossomHill Therapeutics (BLSM) has a Institutional Ownership of 0.00% as of Aug. 10, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on BlossomHill Therapeutics and its competitors.
Is BlossomHill Therapeutics' Institutional Ownership too high?
BlossomHill Therapeutics' current Institutional Ownership is 0.00%. Overall, BlossomHill Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does BlossomHill Therapeutics' Institutional Ownership compare to ?
BlossomHill Therapeutics' Institutional Ownership of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on BlossomHill Therapeutics and its competitors. BlossomHill Therapeutics's current Institutional Ownership is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BlossomHill Therapeutics stock overvalued right now?
BlossomHill Therapeutics (BLSM) has a current Institutional Ownership of 0.00%. The current Institutional Ownership is 0.00%. BlossomHill Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For BlossomHill Therapeutics (BLSM), the current Institutional Ownership is 0.00% as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BlossomHill Therapeutics Business Description

Comparable Companies
Address 10255 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
8GF Score

Get the complete analysis for BLSM

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.02
Price